Zoetis Company Profile (NYSE:ZTS)

About Zoetis (NYSE:ZTS)

Zoetis logoZoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Veterinary Drugs
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:ZTS
  • CUSIP: 98978V10
  • Web: www.zoetis.com
  • Market Cap: $31.38 billion
  • Outstanding Shares: 489,111,000
Average Prices:
  • 50 Day Moving Avg: $62.44
  • 200 Day Moving Avg: $59.64
  • 52 Week Range: $46.86 - $65.83
  • Trailing P/E Ratio: 36.44
  • Foreward P/E Ratio: 23.94
  • P/E Growth: 2.05
Sales & Book Value:
  • Annual Revenue: $5.02 billion
  • Price / Sales: 6.25
  • Book Value: $3.50 per share
  • Price / Book: 18.33
  • Annual Dividend: $0.42
  • Dividend Yield: 0.7%
  • EBIDTA: $1.73 billion
  • Net Margins: 17.50%
  • Return on Equity: 62.49%
  • Return on Assets: 13.14%
  • Debt-to-Equity Ratio: 2.13%
  • Current Ratio: 2.01%
  • Quick Ratio: 1.17%
  • Average Volume: 2.26 million shs.
  • Beta: 1.02
  • Short Ratio: 3.82

Frequently Asked Questions for Zoetis (NYSE:ZTS)

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Friday, May 12th. Stockholders of record on Thursday, June 15th will be paid a dividend of $0.105 per share on Friday, September 1st. This represents a $0.42 annualized dividend and a dividend yield of 0.65%. The ex-dividend date is Tuesday, June 13th. View Zoetis' Dividend History.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) announced its quarterly earnings data on Tuesday, August, 8th. The company reported $0.53 earnings per share for the quarter, missing analysts' consensus estimates of $0.53 by $0.00. The firm had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm's revenue was up 5.0% on a year-over-year basis. During the same period last year, the firm earned $0.49 EPS. View Zoetis' Earnings History.

When will Zoetis make its next earnings announcement?

Zoetis is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Zoetis.

Where is Zoetis' stock going? Where will Zoetis' stock price be in 2017?

17 equities research analysts have issued 1-year price objectives for Zoetis' stock. Their predictions range from $35.00 to $77.00. On average, they anticipate Zoetis' share price to reach $65.12 in the next twelve months. View Analyst Ratings for Zoetis.

What are analysts saying about Zoetis stock?

Here are some recent quotes from research analysts about Zoetis stock:

  • 1. According to Zacks Investment Research, "Zoetis’ growth in revenues is being driven by sales of companion animal products such as Simparica, Apoquel and Cytopoint while the livestock portfolio was driven by growth in swine, cattle and fish across the international markets. Zoetis’ expects to see stronger growth from its companion animal portfolio in 2017 driven by Apoquel and Cytopoint, further penetration of Simparica, and ongoing uptake of new vaccines. Favorable market conditions contributed to swine performance in China as well as cattle product sales in Brazil. Shares of Zoetis have outperformed the industry in 2017 so far. However, disease outbreak among animals is a material cause of concern for Zoetis’ livestock products. Zoetis faces stiff competition from companies like Merck Animal Health (the animal health division of Merck), Elanco (the animal health division of Eli Lilly among others. " (7/4/2017)
  • 2. Guggenheim analysts commented, "We are raising our PT for ZTS shares after a 4Q beat and a lower than expected FX headwind for '17. The increase in our PT is driven by multiple expansion. We arrive at our new PT by using a DCF analysis. ZTS's solid execution this quarter increases our confidence that it can exceed consensus expectations for '17+ and sustain its 21x forward P/E multiple. Upward earnings revisions could come from margin expansion, M&A, and launches. Therefore, the sell-off today, which we think is motivated by profit taking, is overdone, in our view. We believe the weakness (ZTS down 3% vs. S&P down 0.14%) presents a good buying opportunity for the stock." (2/16/2017)

Who are some of Zoetis' key competitors?

Who are Zoetis' key executives?

Zoetis' management team includes the folowing people:

  • Juan Ramon Alaix, Chief Executive Officer, Director
  • Glenn David, Chief Financial Officer, Executive Vice President
  • Roxanne Lagano, Chief Human Resource Officer, Executive Vice President
  • Andrew Fenton, Executive Vice President, Chief Information Officer
  • Heidi C. Chen, Executive Vice President, General Counsel, Corporate Secretary
  • Alejandro Bernal, Executive Vice President, Group President - Strategy, Commercial and Business Development
  • Catherine A. Knupp, Executive Vice President, President - Research and Development
  • Clinton A. Lewis Jr., Executive Vice President, President - International Operations
  • Kristin C. Peck, Executive Vice President, President - U.S. Operations
  • Roman Trawicki, Executive Vice President, President of Global Manufacturing and Supply

Who owns Zoetis stock?

Zoetis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.64%), Vanguard Group Inc. (6.86%), State Street Corp (4.22%), State Farm Mutual Automobile Insurance Co. (3.90%), Alliancebernstein L.P. (2.11%) and Independent Franchise Partners LLP (1.76%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Kristin C Peck, Michael B Mccallister, Pershing Square Capital Manage and Roxanne Lagano. View Institutional Ownership Trends for Zoetis.

Who sold Zoetis stock? Who is selling Zoetis stock?

Zoetis' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Winslow Capital Management LLC, Independent Franchise Partners LLP, Lazard Asset Management LLC, Marshall Wace North America L.P., California Public Employees Retirement System, First Eagle Investment Management LLC and Eaton Vance Management. Company insiders that have sold Zoetis stock in the last year include Catherine A Knupp, Kristin C Peck and Roxanne Lagano. View Insider Buying and Selling for Zoetis.

Who bought Zoetis stock? Who is buying Zoetis stock?

Zoetis' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Alliancebernstein L.P., BlackRock Inc., AJO LP, Harbour Capital Advisors LLC, Thrivent Financial For Lutherans, Northwestern Mutual Investment Management Company LLC and Vanguard Group Inc.. View Insider Buying and Selling for Zoetis.

How do I buy Zoetis stock?

Shares of Zoetis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zoetis' stock price today?

One share of Zoetis stock can currently be purchased for approximately $64.16.

MarketBeat Community Rating for Zoetis (NYSE ZTS)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  436 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  672
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Zoetis (NYSE:ZTS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.65)
Consensus Price Target: $65.12 (1.49% upside)

Analysts' Ratings History for Zoetis (NYSE:ZTS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017Cantor FitzgeraldReiterated RatingBuy$75.00LowView Rating Details
9/1/2017Stifel NicolausReiterated RatingBuy$65.00LowView Rating Details
8/25/2017Piper Jaffray CompaniesSet Price TargetBuy$73.00LowView Rating Details
8/24/2017Cowen and CompanySet Price TargetBuy$70.00LowView Rating Details
8/7/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral -> Neutral$62.00LowView Rating Details
7/25/2017Deutsche Bank AGDowngradeBuy -> Hold$65.00HighView Rating Details
6/20/2017Hilliard LyonsInitiated CoverageBuy$77.00LowView Rating Details
6/13/2017BMO Capital MarketsDowngradeOutperform -> Market Perform$64.00 -> $65.00LowView Rating Details
5/30/2017ArgusReiterated RatingBuy$60.00 -> $69.00LowView Rating Details
5/26/2017CL KingInitiated CoverageBuy -> Buy$71.00LowView Rating Details
5/24/2017Credit Suisse GroupBoost Price TargetOutperform$61.00 -> $67.00LowView Rating Details
5/9/2017Jefferies Group LLCBoost Price TargetBuy$65.00 -> $70.00LowView Rating Details
3/15/2017Craig HallumInitiated CoverageBuy$65.00LowView Rating Details
2/16/2017GuggenheimBoost Price TargetBuy$60.00 -> $65.00N/AView Rating Details
2/16/2017Off Wall StreetReiterated RatingStrong Sell$35.00N/AView Rating Details
11/3/2016J P Morgan Chase & CoReiterated RatingHold$53.00N/AView Rating Details
9/29/2016Bank of America CorporationInitiated CoverageBuy$60.00N/AView Rating Details
8/4/2016Citigroup Inc.Boost Price TargetNeutral$50.00 -> $53.00N/AView Rating Details
8/4/2016Barclays PLCBoost Price TargetEqual Weight$45.00 -> $49.00N/AView Rating Details
1/8/2016Cleveland ResearchInitiated CoverageBuyN/AView Rating Details
(Data available from 9/22/2015 forward)


Earnings History for Zoetis (NYSE:ZTS)
Earnings by Quarter for Zoetis (NYSE:ZTS)
Earnings History by Quarter for Zoetis (NYSE ZTS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017$0.62N/AView Earnings Details
8/8/2017Q2 2017$0.53$0.53$1.27 billion$1.27 billionViewListenView Earnings Details
5/4/2017Q1 2017$0.48$0.53$1.20 billion$1.23 billionViewListenView Earnings Details
2/16/2017Q416$0.45$0.47$1.28 billion$1.30 billionViewN/AView Earnings Details
11/2/2016Q316$0.46$0.52$1.22 billion$1.20 billionViewN/AView Earnings Details
8/3/2016Q216$0.44$0.49$1.17 billion$1.20 billionViewN/AView Earnings Details
5/4/2016Q116$0.41$0.48$1.10 billion$1.20 billionViewN/AView Earnings Details
2/16/2016Q415$0.39$0.43$1.25 billion$1.30 billionViewListenView Earnings Details
11/3/2015Q315$0.40$0.50$1.18 billion$1.20 billionViewN/AView Earnings Details
8/4/2015Q215$0.38$0.43$1.12 billion$1.20 billionViewN/AView Earnings Details
5/5/2015Q115$0.37$0.41$1.11 billion$1.10 billionViewN/AView Earnings Details
2/11/2015Q414$0.36$0.40$1.27 billion$1.30 billionViewN/AView Earnings Details
11/4/2014Q314$0.37$0.41$1.16 billion$1.20 billionViewN/AView Earnings Details
5/6/2014Q114$0.37$0.38$1.13 billion$1.10 billionViewN/AView Earnings Details
2/11/2014Q413$0.34$0.36$1.21 billion$1.25 billionViewN/AView Earnings Details
11/5/2013Q313$0.34$0.34$1.07 billion$1.10 billionViewN/AView Earnings Details
8/6/2013Q2 2013$0.36$0.36$1.13 billion$1.11 billionViewN/AView Earnings Details
4/30/2013Q1 2013$0.27$0.36$1.24 billion$1.09 billionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Zoetis (NYSE:ZTS)
2017 EPS Consensus Estimate: $2.26
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.47$0.49$0.48
Q2 20171$0.50$0.50$0.50
Q3 20171$0.62$0.62$0.62
Q4 20171$0.66$0.66$0.66
(Data provided by Zacks Investment Research)


Current Dividend Information for Zoetis (NYSE:ZTS)
Most Recent Dividend:9/1/2017
Annual Dividend:$0.42
Dividend Yield:0.65%
Dividend Growth:24.90% (3 Year Average)
Payout Ratio:23.73% (Trailing 12 Months of Earnings)
17.95% (Based on This Year's Estimates)
15.67% (Based on Next Year's Estimates)
Track Record:3 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Zoetis (NYSE:ZTS)

Dividend History by Quarter for Zoetis (NYSE ZTS)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Zoetis (NYSE:ZTS)
Insider Ownership Percentage: 0.31%
Institutional Ownership Percentage: 93.20%
Insider Trades by Quarter for Zoetis (NYSE:ZTS)
Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)
Insider Trades by Quarter for Zoetis (NYSE:ZTS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Catherine A KnuppInsiderSell5,785$60.16$348,025.60View SEC Filing  
11/22/2016Kristin C PeckInsiderSell10,092$49.55$500,058.60View SEC Filing  
11/8/2016Roxanne LaganoInsiderSell9,797$50.43$494,062.71View SEC Filing  
9/6/2016Michael B MccallisterDirectorBuy2,000$51.34$102,680.00View SEC Filing  
9/2/2016Andrew FentonInsiderSell13,870$51.25$710,837.50View SEC Filing  
9/1/2016Heidi C ChenInsiderSell32,097$50.98$1,636,305.06View SEC Filing  
5/9/2016Pershing Square Capital ManageDirectorSell16,850,000$46.55$784,367,500.00View SEC Filing  
8/8/2013Michael MccallisterDirectorBuy7,000$31.35$219,450.00View SEC Filing  
2/6/2013Frank A DamelioDirectorBuy5,000$26.00$130,000.00View SEC Filing  
2/6/2013Sandra J BeatyEVPBuy2,000$26.00$52,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Zoetis (NYSE:ZTS)
Latest Headlines for Zoetis (NYSE:ZTS)
americanbankingnews.com logoZoetis Inc. (ZTS) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 17 at 5:08 PM
seekingalpha.com logoZoetis' International Acclaim Demands Attention - Seeking Alpha
seekingalpha.com - September 16 at 10:49 AM
americanbankingnews.com logo Brokerages Anticipate Zoetis Inc. (ZTS) Will Announce Quarterly Sales of $1.33 Billion
www.americanbankingnews.com - September 11 at 2:24 AM
americanbankingnews.com logo$0.63 EPS Expected for Zoetis Inc. (ZTS) This Quarter
www.americanbankingnews.com - September 9 at 8:10 PM
finance.yahoo.com logoZoetis Shows Market Leadership With Jump To 82 RS Rating
finance.yahoo.com - September 8 at 10:55 AM
americanbankingnews.com logoZoetis' (ZTS) Buy Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - September 6 at 1:28 PM
businesswire.com logoZoetis Announces Pricing of $1.25 Billion of Senior Notes - Business Wire (press release)
www.businesswire.com - September 5 at 8:41 PM
finance.yahoo.com logoZoetis Announces Pricing of $1.25 Billion of Senior Notes
finance.yahoo.com - September 5 at 8:41 PM
finance.yahoo.com logoZoetis Inc. -- Moody's assigns Baa1 rating to Zoetis' bond offering
finance.yahoo.com - September 5 at 3:39 PM
nasdaq.com logoNotable ETF Outflow Detected - IWR, PLD, ZTS, FIS - Nasdaq
www.nasdaq.com - September 1 at 3:23 PM
finance.yahoo.com logoZoetis Inc. -- Moody's upgrades Zoetis to Baa1; affirms Prime-2 rating; outlook stable
finance.yahoo.com - September 1 at 11:46 AM
finance.yahoo.com logoZoetis, Inc. breached its 50 day moving average in a Bullish Manner : ZTS-US : September 1, 2017
finance.yahoo.com - September 1 at 11:45 AM
finance.yahoo.com logoZoetis, Inc. breached its 50 day moving average in a Bullish Manner : ZTS-US : September 1, 2017
finance.yahoo.com - September 1 at 11:45 AM
finance.yahoo.com logoEarnings Review and Free Research Report: Zoetis’ Results Beat Estimates in EPS and Revenues; Updated Full Year Guidance
finance.yahoo.com - August 28 at 7:59 AM
finance.yahoo.com logoEarnings Review and Free Research Report: Zoetis’ Results Beat Estimates in EPS and Revenues; Updated Full Year Guidance
finance.yahoo.com - August 28 at 7:59 AM
americanbankingnews.com logoZoetis Inc. (ZTS) Given a $73.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - August 26 at 8:32 PM
finance.yahoo.com logoThese Healthcare Stocks Are for the Dogs -- but They're Barking Up the Right Tree for Investors
finance.yahoo.com - August 25 at 6:09 PM
americanbankingnews.com logoCowen and Company Analysts Give Zoetis Inc (ZTS) a $70.00 Price Target
www.americanbankingnews.com - August 24 at 6:28 PM
americanbankingnews.com logoZoetis Inc (ZTS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - August 23 at 6:46 PM
streetinsider.com logoZoetis (ZTS): Clavamox Chewable antibiotic Study Success Underscores Positive Thesis - Cantor - StreetInsider.com
www.streetinsider.com - August 15 at 8:42 AM
americanbankingnews.com logoZoetis Inc. (NYSE:ZTS) PT Set at $75.00 by Cantor Fitzgerald
www.americanbankingnews.com - August 14 at 3:34 PM
americanbankingnews.com logoFY2017 Earnings Forecast for Zoetis Inc. Issued By Cantor Fitzgerald (NYSE:ZTS)
www.americanbankingnews.com - August 14 at 3:52 AM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Zoetis Inc.
finance.yahoo.com - August 11 at 9:24 AM
americanbankingnews.com logoFY2017 Earnings Forecast for Zoetis Inc. (NYSE:ZTS) Issued By Gabelli
www.americanbankingnews.com - August 10 at 12:10 PM
americanbankingnews.com logoBrokers Issue Forecasts for Zoetis Inc.'s FY2017 Earnings (NYSE:ZTS)
www.americanbankingnews.com - August 10 at 12:10 PM
finance.yahoo.com logoEdited Transcript of ZTS earnings conference call or presentation 8-Aug-17 12:30pm GMT
finance.yahoo.com - August 10 at 1:38 AM
finance.yahoo.com logoZoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View - Yahoo Finance
finance.yahoo.com - August 9 at 8:37 PM
nasdaq.com logoZoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View - Nasdaq
www.nasdaq.com - August 9 at 3:34 PM
streetinsider.com logoUPDATE: Goldman Sachs Reinstates Zoetis Inc. (ZTS) at Neutral - StreetInsider.com
www.streetinsider.com - August 9 at 3:34 PM
seekingalpha.com logoZoetis (ZTS) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 9:31 AM
americanbankingnews.com logoZoetis Inc. (ZTS) Announces Earnings Results, Hits Estimates
www.americanbankingnews.com - August 8 at 9:42 AM
finance.yahoo.com logoZoetis, Inc. – Value Analysis (NYSE:ZTS) : August 7, 2017
finance.yahoo.com - August 8 at 8:34 AM
finance.yahoo.com logoZoetis Announces Second Quarter 2017 Results
finance.yahoo.com - August 8 at 8:34 AM
finance.yahoo.com logoZoetis meets 2Q profit forecasts
finance.yahoo.com - August 8 at 8:34 AM
finance.yahoo.com logoZoetis (ZTS) Q2 Earnings In-line, Sales Beat; 2017 View Up
finance.yahoo.com - August 8 at 8:34 AM
zacks.com logoShould You Buy Zoetis (ZTS) Ahead of Earnings?
www.zacks.com - August 7 at 8:52 AM
americanbankingnews.com logoZoetis Inc. (ZTS) Expected to Announce Quarterly Sales of $1.25 Billion
www.americanbankingnews.com - August 6 at 9:14 AM
finance.yahoo.com logoZoetis Appoints Dr. Linda Rhodes to Board of Directors
finance.yahoo.com - August 4 at 10:20 AM
americanbankingnews.com logo$0.53 EPS Expected for Zoetis Inc. (ZTS) This Quarter
www.americanbankingnews.com - August 4 at 8:02 AM
finance.yahoo.com logoETFs with exposure to Zoetis, Inc. : August 1, 2017
finance.yahoo.com - August 2 at 9:01 AM
americanbankingnews.com logoZoetis Inc. (NYSE:ZTS) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:16 AM
finance.yahoo.com logoZoetis Completes Acquisition of Nexvet Biopharma
finance.yahoo.com - July 31 at 8:22 AM
americanbankingnews.com logoZoetis Inc. (NYSE:ZTS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - July 29 at 4:43 PM
americanbankingnews.com logoFinancial Comparison: Zoetis (NYSE:ZTS) & Aratana Therapeutics (PETX)
www.americanbankingnews.com - July 29 at 7:21 AM
nasdaq.com logoYieldBoost Zoetis From 0.7% To 2.8% Using Options - Nasdaq
www.nasdaq.com - July 28 at 10:21 AM
americanbankingnews.com logoZoetis (NYSE:ZTS) versus Aratana Therapeutics (PETX) Critical Survey
www.americanbankingnews.com - July 28 at 8:11 AM
benzinga.com logoZoetis Investors May Need Patience To See Bull Thesis Play Out - Benzinga
www.benzinga.com - July 27 at 9:56 AM
streetinsider.com logoUPDATE: Deutsche Bank Downgrades Zoetis Inc. (ZTS) to Hold - StreetInsider.com
www.streetinsider.com - July 27 at 9:55 AM
streetinsider.com logoUPDATE: Deutsche Bank Downgrades Zoetis Inc. (ZTS) to Hold
www.streetinsider.com - July 26 at 10:45 AM
finance.yahoo.com logoZoetis, Inc. breached its 50 day moving average in a Bearish Manner : ZTS-US : July 26, 2017
finance.yahoo.com - July 26 at 10:45 AM



Zoetis (ZTS) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff